OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care SOUTH... Read more.
Exit Partners Advises Casa de Perrin on Strategic Sale to Curated Events
DALLAS–(BUSINESS WIRE)–Exit Partners, a boutique investment banking and M&A advisory firm specializing in founder-led businesses, today announced... Read more.
Exit Partners Advises Casa de Perrin on Strategic Sale to Curated Events
DALLAS–(BUSINESS WIRE)–Exit Partners, a boutique investment banking and M&A advisory firm specializing in founder-led businesses, today announced... Read more.
Guidewire to Announce Third Quarter Fiscal Year 2026 Financial Results on June 4, 2026
SAN MATEO, Calif.–(BUSINESS WIRE)–Guidewire (NYSE: GWRE) announced that it will release its financial results for the fiscal quarter ended April 30,... Read more.
Guidewire to Announce Third Quarter Fiscal Year 2026 Financial Results on June 4, 2026
SAN MATEO, Calif.–(BUSINESS WIRE)–Guidewire (NYSE: GWRE) announced that it will release its financial results for the fiscal quarter ended April 30,... Read more.
Copart Reports Third Quarter Fiscal 2026 Financial Results
DALLAS–(BUSINESS WIRE)–Copart, Inc. (NASDAQ: CPRT) today reported financial results for the quarter ended April 30, 2026. For the three months ended... Read more.
Copart Reports Third Quarter Fiscal 2026 Financial Results
DALLAS–(BUSINESS WIRE)–Copart, Inc. (NASDAQ: CPRT) today reported financial results for the quarter ended April 30, 2026. For the three months ended... Read more.
Nametag Launches Nametag Recruit, Bringing Identity Assurance to Enterprise Hiring
Integrated with Workday and Greenhouse, Recruit completes the Nametag Hire solution, enabling enterprises to verify candidate identity across the entire hiring lifecycle.... Read more.
NomosLogic Brings Deterministic Molecular Medicine Infrastructure to BIO International Convention 2026 as Adverse Drug Reactions Continue to Cost $30 Billion and 100,000 American Lives Each Year
Salt Lake City-based infrastructure company addresses the architectural failure underneath three decades of population-averaged precision medicine, with founder... Read more.
NomosLogic Brings Deterministic Molecular Medicine Infrastructure to BIO International Convention 2026 as Adverse Drug Reactions Continue to Cost $30 Billion and 100,000 American Lives Each Year
Salt Lake City-based infrastructure company addresses the architectural failure underneath three decades of population-averaged precision medicine, with founder... Read more.